|Trade names||Losec, Prilosec, Zegerid, others|
|Drug class||Proton-pump inhibitor|
|Main uses||GERD, stomach ulcers|
|By mouth, IV|
|Defined daily dose||20 mg|
|Metabolism||Hepatic (CYP2C19, CYP3A4)|
|Elimination half-life||1–1.2 hours|
20% (bile via feces)
|Chemical and physical data|
|Molar mass||345.42 g·mol−1|
|3D model (JSmol)|
|Melting point||156 °C (313 °F)|
Omeprazole, sold under the brand names Prilosec and Losec among others, is a medication used in the treatment of gastroesophageal reflux disease (GERD), peptic ulcer disease, and Zollinger–Ellison syndrome. It is also used to prevent upper gastrointestinal bleeding in people who are at high risk. Omeprazole is a proton-pump inhibitor (PPI) and its effectiveness is similar to other PPIs. It can be taken by mouth or by injection into a vein.
Common side effects include nausea, vomiting, headaches, abdominal pain, and increased intestinal gas. Serious side effects may include Clostridium difficile colitis, an increased risk of pneumonia, an increased risk of bone fractures, and the potential of masking stomach cancer. It is unclear if it is safe for use in pregnancy. It works by blocking the release of stomach acid.
Omeprazole was patented in 1978, and approved for medical use in 1988. It is on the World Health Organization's List of Essential Medicines. It is available as a generic medication. The wholesale cost in the developing world as of 2014[update], is US$0.01 to US$0.07 per dose. In the United States, it costs on average US$0.50 per pill. In 2017, it was the seventh most commonly prescribed medication in the United States, with more than 58 million prescriptions. It is also available without a prescription in the United States.
Peptic ulcers may be treated with omeprazole. Treatment of a Helicobacter pylori infection can be completed by taking a triple therapy combination of omeprazole, amoxicillin, and clarithromycin for 7–14 days. Amoxicillin may be replaced with metronidazole in people who are allergic to penicillin.
The defined daily dose is 20 mg by mouth or by injection. The typical dose is adults and children over 20 kg is 20 mg in the morning by mouth. For those who weight 10 to 20 kg, 10 mg by mouth is used while in those who weight 5 to 10 kg, the dose is 5 mg. By injection 40 mg once per day may be used.
Side effects occurring in at least 1% of people include:
- Central nervous system: headache (7%), dizziness (2%)
- Respiratory: upper respiratory tract infection (2%), cough (1%)
- Gastrointestinal: abdominal pain (5%), diarrhea (4%), nausea (4%), vomiting (3%), flatulence (3%), acid regurgitation (2%), constipation (2%)
- Neuromuscular and skeletal: back pain (1%), weakness (1%)
- Skin: rash (2%)
Other concerns are:
- Recurrence of Clostridium difficile associated diarrhea
- Osteoporosis-related fractures
- Low blood magnesium
Concern has been expressed regarding vitamin B12 and iron malabsorption, but effects seem to be insignificant, especially when supplement therapy is provided.Since their introduction, proton-pump inhibitors (PPIs, especially omeprazole) have also been associated with several cases of acute interstitial nephritis, an inflammation of the kidneys that occurs as an adverse drug reaction.
Long-term use of PPIs is strongly associated with the development of benign polyps from fundic glands (which is distinct from fundic gland polyposis); these polyps do not cause cancer and resolve when PPIs are discontinued. No association is seen between PPI use and cancer, but use of PPIs may mask gastric cancers or other serious gastric problems and physicians should be aware of this effect.There is a tentative association between long term use and dementia which requires further study to confirm.
Pregnancy and breast-feeding
The safety of using omeprazole has not been established in pregnant or breast-feeding women. Epidemiological data do not show an increased risk of major birth defects after maternal use of omeprazole during pregnancy.The pharmacokinetics of the omeprazole molecule suggest the relative safety of omeprazole use during breastfeeding:
- Omeprazole has a high plasma protein binding rate (95%), indicating that little amount of drug is transferred to the milk duct during breast milk formation.
- Omeprazole needs to be administrated in an enteric-coated formulation due to its rapid degradation in the acidic conditions of the stomach.
Important drug interactions are rare. However, the most significant major drug interaction concern is the decreased activation of clopidogrel when taken together with omeprazole. Although still controversial, this may increase the risk of stroke or heart attack in people taking clopidogrel to prevent these events.
This interaction is possible because omeprazole is an inhibitor (reversibly inhibits) of the enzymes CYP2C19 and CYP3A4. Clopidogrel is an inactive prodrug that partially depends on CYP2C19 for conversion to its active form. Inhibition of CYP2C19 may block the activation of clopidogrel, which could reduce its effects.
Almost all benzodiazepines are metabolised by the CYP3A4 and CYP2D6 pathways, and inhibition of these enzymes results in a higher AUC (i.e., the total effect over time of a given dose). Other examples of drugs dependent on CYP3A4 for their metabolism are escitalopram, warfarin, oxycodone, and tramadol. Omeprazole is also a competitive inhibitor of p-glycoprotein, as are other PPIs.Drugs that depend on an acidic stomach environment (such as ketoconazole or atazanavir) may be poorly absorbed, whereas acid-labile antibiotics, such as erythromycin, may be absorbed to a greater extent than normal due to the more alkaline environment of the stomach.
St. John's wort (Hypericum perforatum) and Gingko biloba significantly reduce plasma concentrations of omeprazole through induction of CYP3A4 and CYP2C19.Proton-pump inhibitors like omeprazole have been found to increase the plasma concentrations of methotrexate.
Omeprazole irreversibly blocks the enzyme system on parietal cells that is needed for secretion of gastric acid. It is a specific H+/K+ATPase inhibitor. This is the enzyme needed for the final step in secretion of gastric acid.
Mechanism of action
Omeprazole is a selective and irreversible proton pump inhibitor. It suppresses stomach acid secretion by specific inhibition of the H+/K+-ATPase system found at the secretory surface of gastric parietal cells. Because this enzyme system is regarded as the acid (proton, or H+) pump within the gastric mucosa, omeprazole inhibits the final step of acid production.Omeprazole also inhibits both basal and stimulated acid secretion irrespective of the stimulus as it blocks the last step in acid secretion.
The inhibitory effect of omeprazole occurs within 1 hour after oral administration. The maximum effect occurs within 2 hours. The duration of inhibition is up to 72 hours. When omeprazole is stopped, baseline stomach acid secretory activity returns after 3 to 5 days. The inhibitory effect of omeprazole on acid secretion will plateau after 4 days of repeated daily dosing.
The absorption of omeprazole takes place in the small intestine and is usually completed within 3 to 6 hours. The systemic bioavailability of omeprazole after repeated doses is about 60%. Omeprazole has a volume of distribution of 0.4 L/kg. It has high plasma protein binding of 95%.
Omeprazole, as well as other PPIs, are only effective on active H+/K+-ATPase pumps. These pumps are stimulated in the presence of food to aid in digestion. For this reason, patients should be advised to take omeprazole with a glass of water on an empty stomach. Additionally, most sources recommend that after taking omeprazole, at least 30 minutes should be allowed to elapse before eating (at least 60 minutes for immediate-release omeprazole plus sodium bicarbonate products, such as Zegerid), though some sources say that with delayed-release forms of omeprazole, waiting before eating after taking the medication is not necessary.
Omeprazole is completely metabolized by the cytochrome P450 system, mainly in the liver, by CYP2C19 and CYP3A4 isoenzymes. Identified metabolites are the sulfone, the sulfide, and hydroxy-omeprazole, which exert no significant effect on acid secretion. About 77% of an orally given dose is excreted as metabolites in the urine, and the remainder is found in the feces, primarily originating from bile secretion. Omeprazole has a half life of 0.5 to 1 hour, the pharmacological effects of omeprazole last longer as it is covalently bonded to proton pump on parietal cells 
Omeprazole contains a tricoordinated sulfinyl sulfur in a pyramidal structure and therefore can exist as either the (S)- or (R)-enantiomers, omeprazole is a racemate, an equal mixture of the two. In the acidic conditions of the canaliculi of parietal cells, both enantiomers are converted to achiral products which react with a cysteine group in H+/K+ ATPase, thereby inhibiting the ability of the parietal cells to produce gastric acid.
AstraZeneca also developed esomeprazole (Nexium), which is the enantiomer, to (R) omeprazole.Omeprazole undergoes a chiral shift in vivo which converts the inactive (R)-enantiomer to the active (S)-enantiomer, doubling the concentration of the active form. This chiral shift is accomplished by the CYP2C19 isozyme of cytochrome P450, which is not found equally in all human populations. Those who do not metabolize the drug effectively are called "poor metabolizers". The proportion of the poor metabolizer phenotype varies widely between populations, from 2.0–2.5% in African Americans and white Americans to >20% in Asians. Several pharmacogenomics studies have suggested that PPI treatment should be tailored according to CYP2C19 metabolism status.
Measurement in body fluids
Omeprazole may be quantified in plasma or serum to monitor therapy or to confirm a diagnosis of poisoning in hospitalized patients. Plasma omeprazole concentrations are usually in a range of 0.2–1.2 mg/l in persons receiving the drug therapeutically by the oral route and 1–6 mg/l in victims of acute overdose. Enantiomeric chromatographic methods are available to distinguish esomeprazole from racemic omeprazole.
Omeprazole was first made in 1979 by Swedish AB Hässle, part of Astra AB. It was the first of the proton pump inhibitors (PPI). Astra AB, now AstraZeneca, launched it as an ulcer medicine under the name Losec in Sweden. It was first sold in the United States in 1989 under the brand name Losec. In 1990, at the request of the U.S. Food and Drug Administration, the brand name Losec was changed to Prilosec to avoid confusion with the diuretic Lasix (furosemide). The new name led to confusion between omeprazole (Prilosec) and fluoxetine (Prozac), an antidepressant.When Prilosec's U.S. patent expired in April 2001, AstraZeneca introduced esomeprazole (Nexium) as a patented replacement drug.
Society and culture
The wholesale cost in the developing world as of 2014[update], is US$0.01 to US$0.07 per dose. In the United States, it costs on average US$0.50 per pill. In 2017, it was the seventh most commonly prescribed medication in the United States, with more than 58 million prescriptions.
Omeprazole is available in strengths of 10, 20, 40, and in some markets 80 mg; and as a powder (omeprazole sodium) for intravenous injection. Most oral omeprazole preparations are enteric-coated, due to the rapid degradation of the drug in the acidic conditions of the stomach. This is most commonly achieved by formulating enteric-coated granules within capsules, enteric-coated tablets, and the multiple-unit pellet system (MUPS). An immediate release formulation was approved by the FDA in the United States, which does not require enteric coating.
It is also available for use in injectable form (IV) in Europe, but not in the U.S.
- "Omeprazole". The American Society of Health-System Pharmacists. Retrieved 21 October 2018.
- "Omeprazole international". Drugs.com. 3 February 2020. Retrieved 27 February 2020.
- "OMEPRAZOLE oral - Essential drugs". medicalguidelines.msf.org. Retrieved 22 August 2020. CS1 maint: discouraged parameter (link)
- "Omeprazole Use During Pregnancy". Drugs.com. 11 April 2019. Retrieved 15 February 2020.
- "WHOCC - ATC/DDD Index". www.whocc.no. Retrieved 1 September 2020. CS1 maint: discouraged parameter (link)
- "Prilosec- omeprazole magnesium capsule, delayed release Prilosec- omeprazole magnesium granule, delayed release". DailyMed. 22 December 2016. Retrieved 15 February 2020.
- Vaz-Da-Silva, Manuel; Loureiro, Ana I.; Nunes, Teresa; Maia, Joana; Tavares, Susana; Falcão, Amilcar; Silveira, Pedro; Almeida, Luis; Soares-Da-Silva, Patricio (2005). "Bioavailability and Bioequivalence of Two Enteric-Coated Formulations of Omeprazole in Fasting and Fed Conditions". Clinical Drug Investigation. 25 (6): 391–399. doi:10.2165/00044011-200525060-00004. PMID 17532679. S2CID 22082780. Archived from the original on 13 March 2013. Retrieved 21 October 2018.
- "Omeprazole MSDS". Retrieved 21 October 2018.
- " Comparative effectiveness of proton pump inhibitors | Therapeutics Initiative". 28 June 2016. Retrieved 14 July 2016. CS1 maint: discouraged parameter (link)
- "Omeprazole 40 mg Powder for Solution for Infusion". EMC. 10 February 2016. Archived from the original on 7 April 2016. Retrieved 21 October 2018.
- Vallerand, A.H.; Sanoski, C.A.; Deglin, J.H. (2015). Davis's Drug Guide for Nurses (14th ed.). F.A. Davis Company. pp. 924–925. ISBN 978-0-8036-4085-6. OCLC 881473728.
- Fischer, Jnos; Ganellin, C. Robin (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 445. ISBN 9783527607495.
- World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.
- "Omeprazole". International Drug Price Indicator Guide. Archived from the original on 10 May 2017. Retrieved 21 October 2018.[dead link]
- "NADAC as of 2016-11-16 Data.Medicaid.gov". Centers for Medicare and Medicaid Services. Archived from the original on 17 November 2016. Retrieved 21 October 2018.
- "The Top 300 of 2020". ClinCalc. 23 December 2019. Retrieved 27 February 2020.
- "Omeprazole - Drug Usage Statistics, ClinCalc DrugStats Database". ClinCalc. 23 December 2019. Retrieved 27 February 2020.
- Research, Center for Drug Evaluation and (3 November 2018). "Questions and Answers on Prilosec OTC (omeprazole)". FDA. Retrieved 2 March 2020. CS1 maint: discouraged parameter (link)
- Cheng, Edaire (21 July 2013). "Proton Pump Inhibitors for Eosinophilic Esophagitis". Current Opinion in Gastroenterology. 29 (4): 416–420. doi:10.1097/MOG.0b013e32835fb50e. ISSN 0267-1379. PMC 4118554. PMID 23449027.
- Fuccio, Lorenzo; Minardi, Maria Eugenia; Zagari, Rocco Maurizo; Grilli, Diego; Magrini, Nicola; Bazzoli, Franco (2007). "Meta-analysis: Duration of First-Line Proton-Pump Inhibitor–Based Triple Therapy for Helicobacter pylori Eradication". Annals of Internal Medicine. 147 (8): 553–62. doi:10.7326/0003-4819-147-8-200710160-00008. PMID 17938394. S2CID 11644009.
- Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ (21 June 2007). "Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report". Gut. 56 (6): 772–81. doi:10.1136/gut.2006.101634. PMC 1954853. PMID 17170018.
- "OMEPRAZOLE injectable - Essential drugs". medicalguidelines.msf.org. Retrieved 4 September 2020. CS1 maint: discouraged parameter (link)
- McTavish D, Buckley MM, Heel RC (1991). "Omeprazole. An updated review of its pharmacology and therapeutic use in acid-related disorders". Drugs. 42 (1): 138–70. doi:10.2165/00003495-199142010-00008. PMID 1718683.
- Abou Chakra, CN; et al. (21 June 2014). "Risk factors for recurrence, complications and mortality in Clostridium difficile infection: a systematic review". PLOS ONE. 9 (6): e98400. Bibcode:2014PLoSO...998400A. doi:10.1371/journal.pone.0098400. PMC 4045753. PMID 24897375.
- Yang, Yu-Xiao; et al. (2006). "Long-term proton pump inhibitor therapy and risk of hip fracture". JAMA. 296 (24): 2947–2953. doi:10.1001/jama.296.24.2947. PMID 17190895.
- Yu, Elaine W.; et al. (2011). "Proton pump inhibitors and risk of fractures: a meta-analysis of 11 international studies". The American Journal of Medicine. 124 (6): 519–526. doi:10.1016/j.amjmed.2011.01.007. PMC 3101476. PMID 21605729.
- Hess, M. W.; et al. (2012). "Systematic review: hypomagnesaemia induced by proton pump inhibition". Alimentary Pharmacology & Therapeutics. 36 (5): 405–413. doi:10.1111/j.1365-2036.2012.05201.x. PMID 22762246.
- McColl, Kenneth EL (2009). "Effect of proton pump inhibitors on vitamins and iron". The American Journal of Gastroenterology. 104: S5–S9. doi:10.1038/ajg.2009.45. PMID 19262546. S2CID 31455416.
- Sarzynski, Erin; et al. (2011). "Association between proton pump inhibitor use and anemia: a retrospective cohort study". Digestive Diseases and Sciences. 56 (8): 2349–2353. doi:10.1007/s10620-011-1589-y. PMID 21318590. S2CID 33574008.
- Greenberg, Arthur (2009). Primer on kidney diseases (5th ed.). Philadelphia, PA: Saunders/Elsevier. p. 369. ISBN 978-1-4377-2110-2. Retrieved 18 October 2020. CS1 maint: discouraged parameter (link)
- Corleto, V.D. (21 February 2014). "Proton pump inhibitor therapy and potential long-term harm". Curr Opin Endocrinol Diabetes Obes. 21 (1): 3–8. doi:10.1097/med.0000000000000031. PMID 24310148.
- Eusebi, LH; Rabitti, S; Artesiani, ML; Gelli, D; Montagnani, M; Zagari, RM; Bazzoli, F (21 July 2017). "Proton pump inhibitors: Risks of long-term use". Journal of Gastroenterology and Hepatology. 32 (7): 1295–1302. doi:10.1111/jgh.13737. PMID 28092694.
- Pasternak, Björn; Hviid, Anders (2010). "Use of Proton-Pump Inhibitors in Early Pregnancy and the Risk of Birth Defects". New England Journal of Medicine. 363 (22): 2114–23. doi:10.1056/NEJMoa1002689. PMID 21105793. S2CID 10954538.
- "Omeprazole: medicine to reduce stomach acid". nhs.uk. 29 August 2018. Retrieved 20 October 2020. CS1 maint: discouraged parameter (link)
- "LACTMED: OMEPRAZOLE". 10 March 2015. Archived from the original on 8 September 2017. Retrieved 21 October 2018.
- "Omeprazole drug summary". PDR.net. Archived from the original on 3 March 2014. Retrieved 21 October 2018.
- Olbe, Lars. Proton Pump Inhibitors. Birkhäuser. p. 164. ISBN 978-3-0348-8795-3. Retrieved 19 October 2020. CS1 maint: discouraged parameter (link)
- "Proton Pump Inhibitor: Use in Adults" (PDF). CMS Medicaid Integrity Program. Archived from the original (PDF) on 12 December 2013. Retrieved 21 October 2018.
- Douglas, I. J.; Evans, S. J.; Hingorani, A. D.; Grosso, A. M.; Timmis, A; Hemingway, H; Smeeth, L (2012). "Clopidogrel and interaction with proton pump inhibitors: comparison between cohort and within person study designs". BMJ. 345: e4388. doi:10.1136/bmj.e4388. PMC 3392956. PMID 22782731.
- Focks, J. J.; Brouwer, M. A.; Van Oijen, M. G. H.; Lanas, A.; Bhatt, D. L.; Verheugt, F. W. A. (2012). "Concomitant use of clopidogrel and proton pump inhibitors: Impact on platelet function and clinical outcome- a systematic review". Heart. 99 (8): 520–7. doi:10.1136/heartjnl-2012-302371. PMID 22851683. S2CID 23689175.
- Di, Li; Kerns, Edward H. Drug-Like Properties : Concepts, Structure Design and Methods from ADME to Toxicity Optimization (2nd ed.). p. 236. ISBN 978-0-12-801322-9. Retrieved 20 October 2020. CS1 maint: discouraged parameter (link)
- Norgard NB, Mathews KD, Wall GC (July 2009). "Drug-drug interaction between clopidogrel and the proton pump inhibitors". Ann Pharmacother. 43 (7): 1266–1274. doi:10.1345/aph.1M051. PMID 19470853. S2CID 13227312.
- Selective Serotonin Reuptake Inhibitors and CYP2D6 at eMedicine
- Crader, Marsha F.; Johns, Tracy; Arnold, Justin K. (2020). "Warfarin Drug Interactions". StatPearls. StatPearls Publishing. Retrieved 24 October 2020. CS1 maint: discouraged parameter (link)
- Q. Ashton, Acton (2012). Drug Classes-Advances in Research and Application. Atlanta: ScholarlyMedia LLC. p. 313. ISBN 978-1-4649-9313-8. Retrieved 24 October 2020. CS1 maint: discouraged parameter (link)
- "Critical review report Tramadol" (PDF). WHO. World Health Organization. Retrieved 24 October 2020. CS1 maint: discouraged parameter (link)
- Li, Wei; Zeng, Su; Yu, Lu-Shan; Zhou, Quan (2013). "Pharmacokinetic drug interaction profile of omeprazole with adverse consequences and clinical risk management". Therapeutics and Clinical Risk Management. 9: 259–271. doi:10.2147/TCRM.S43151. ISSN 1176-6336. Retrieved 24 October 2020. CS1 maint: discouraged parameter (link)
- Lahner, E.; Annibale, B.; Fave, G. Delle (2009). "Systematic review: impaired drug absorption related to the co-administration of antisecretory therapy". Alimentary Pharmacology & Therapeutics. 29 (12): 1219–1229. doi:10.1111/j.1365-2036.2009.03993.x. ISSN 1365-2036. Retrieved 30 October 2020. CS1 maint: discouraged parameter (link)
- Shargel, Leon; Yu, Andrew B. C. Applied Biopharmaceutics & Pharmacokinetics, Seventh Edition. McGraw Hill Professional. p. 421. ISBN 978-0-07-182964-9. Retrieved 31 October 2020. CS1 maint: discouraged parameter (link)
- Izzo, AA; Ernst, E (2009). "Interactions between herbal medicines and prescribed drugs: an updated systematic review". Drugs. 69 (13): 1777–1798. doi:10.2165/11317010-000000000-00000. PMID 19719333. S2CID 25720882.
- Brayfield, A, ed. (6 January 2014). "Methotrexate". Martindale: The Complete Drug Reference. Pharmaceutical Press. Retrieved 12 April 2014. CS1 maint: discouraged parameter (link)
- Howden, CW (January 1991). "Clinical pharmacology of omeprazole". Clinical Pharmacokinetics. 20 (1): 38–49. doi:10.2165/00003088-199120010-00003. PMID 2029801. S2CID 25855436.
- Shah, Neal; Gossman, William (2020). "Omeprazole". StatPearls. StatPearls Publishing. Retrieved 31 October 2020. CS1 maint: discouraged parameter (link)
- "Omeprazole". www.drugbank.ca. Retrieved 29 January 2019. CS1 maint: discouraged parameter (link)
- Omeprazole [package insert]. Archived 19 April 2014 at the Wayback Machine India: Dr. Reddy's Laboratories Limited. Revised: 0613
- White, Rebecca; Bradnam, Vicky. Handbook of Drug Administration via Enteral Feeding Tubes, 3rd edition. Pharmaceutical Press. p. 519. ISBN 978-0-85711-162-3. Retrieved 24 October 2020. CS1 maint: discouraged parameter (link)
- Scarth, Edward; Smith, Susan. Drugs in Anaesthesia and Intensive Care. Oxford University Press. p. 282. ISBN 978-0-19-876881-4. Retrieved 24 October 2020. CS1 maint: discouraged parameter (link)
- Katz, PO; Gerson, LB; Vela, MF (2013). "Guidelines for the diagnosis and management of gastroesophageal reflux disease". Am J Gastroenterol. 108 (3): 308–28. doi:10.1038/ajg.2012.444. PMID 23419381. S2CID 8198975.
- "Omeprazole, in The Free Medical Dictionary". Retrieved 11 November 2010. CS1 maint: discouraged parameter (link)
- "Omeprazole". Drugs.com. Archived from the original on 19 February 2011. Retrieved 11 November 2010. CS1 maint: discouraged parameter (link)
- "Zegird, How to take". rxlist.com. Archived from the original on 26 October 2010. Retrieved 11 November 2010. CS1 maint: discouraged parameter (link)
- essential drug information. MIMS USA. Retrieved 20 December 2009.
- Avunduk, Canan. Manual of Gastroenterology: Diagnosis and Therapy. Lippincott Williams & Wilkins. p. 164. ISBN 978-0-7817-6974-7. Retrieved 22 October 2020. CS1 maint: discouraged parameter (link)
- "Omeprazole". pubchem.ncbi.nlm.nih.gov. Retrieved 25 October 2020. CS1 maint: discouraged parameter (link)
- "Esomeprazole". pubchem.ncbi.nlm.nih.gov. Retrieved 25 October 2020. CS1 maint: discouraged parameter (link)
- Nexium Prescribing Information Archived 8 October 2009 at the Wayback Machine. AstraZeneca Pharmaceuticals.
- Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T (June 2005). "Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies". Drug Metab Pharmacokinet. 20 (3): 153–67. doi:10.2133/dmpk.20.153. PMID 15988117.
- Baselt RC, Disposition of Toxic Drugs and Chemicals in Man, 8th edition, Biomedical Publications, Foster City, CA, 2008, pp. 1146–7. ISBN 978-0-9626523-7-0.
- "Trends in Drug Patenting - Case Studies: THE CASES: 5. OMEPRAZOLE". apps.who.int. Retrieved 22 August 2019.
- Fellenius, Erik; Berglindh, Thomas; Sachs, George; Olbe, Lars; Elander, Berit; Sjöstrand, Sven-Erik; Wallmark, Björn (1981). "Substituted benzimidazoles inhibit gastric acid secretion by blocking (H+ + K+) ATPase". Nature. 290 (5802): 159–61. Bibcode:1981Natur.290..159F. doi:10.1038/290159a0. PMID 6259537. S2CID 4368190.
- Farley, D (July–August 1995). "Making it easier to read prescriptions". FDA Consum. 29 (6): 25–7. PMID 10143448. Archived from the original on 15 March 2012. Retrieved 26 January 2011. CS1 maint: discouraged parameter (link)
- Gardiner Harris (6 June 2002). "Prilosec's Maker Switches Users To Nexium, Thwarting Generics". The Wall Street Journal. Archived from the original on 6 August 2017. CS1 maint: discouraged parameter (link)
- Cite error: Invalid
<ref>tag; no text was provided for refs named
- "Prilosec (omeprazole) dosing, indications, interactions, adverse effects, and more". reference.medscape.com. Retrieved 19 October 2020. CS1 maint: discouraged parameter (link)
- "Omeprazole sodium". pubchem.ncbi.nlm.nih.gov. Retrieved 19 October 2020. CS1 maint: discouraged parameter (link)
- Ainsworth, Sean. Neonatal formulary : drug use in pregnancy and the first year of life (Eighth ed.). Oxford. p. 571. ISBN 978-0-19-257727-6. Retrieved 19 October 2020. CS1 maint: discouraged parameter (link)
- Santarus. Santarus Receives FDA Approval for Immediate-Release Omeprazole Tablet with Dual Buffers. Archived 18 April 2014 at Archive.today N.p., 4 December 2009. Web. 18 April 2014.
- Pang, Sandy H.; Graham, David Y. "A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers". Therapeutic Advances in Gastroenterology. 3 (1): 11–22. doi:10.1177/1756283X09352095. ISSN 1756-283X. Retrieved 19 October 2020. CS1 maint: discouraged parameter (link)
- Dean L (2012). "Omeprazole Therapy and CYP2C19 Genotype". In Pratt VM, McLeod HL, Rubinstein WS, et al. (eds.). Medical Genetics Summaries. National Center for Biotechnology Information (NCBI). PMID 28520353. Bookshelf ID: NBK100895.